Equities

Liquidia Corp

Liquidia Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.95
  • Today's Change-0.32 / -3.12%
  • Shares traded1.54m
  • 1 Year change+58.44%
  • Beta0.2216
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

  • Revenue in USD (TTM)14.84m
  • Net income in USD-112.11m
  • Incorporated2020
  • Employees136.00
  • Location
    Liquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
  • Phone+1 (919) 328-4400
  • Fax+1 (919) 328-4402
  • Websitehttps://www.liquidia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kalvista Pharmaceuticals Inc0.00-141.77m453.33m150.00--2.62-----3.54-3.540.004.010.00----0.00-78.65-40.63-87.52-43.67-------2,972.81----0.00-------36.31---16.34--
Aquestive Therapeutics Inc58.36m-25.72m463.49m135.00------7.94-0.3565-0.35650.7874-0.38960.66852.857.25432,296.30-29.46-76.63-42.14-123.8568.4964.24-44.07-102.956.98-2.67----6.09-5.5985.54---11.42--
Eyepoint Pharmaceuticals Inc50.39m-86.82m476.85m121.00--2.04--9.46-1.80-1.801.084.380.20161.108.18416,454.50-34.74-40.44-47.07-47.7991.3583.45-172.29-186.234.69--0.00--11.14--30.77------
SNDL Inc672.06m-83.20m527.50m2.52k--0.5812--0.7849-0.3185-0.31852.563.420.59884.6333.15267,115.60-7.67-24.44-8.32-27.9425.0422.49-12.82-62.172.98--0.1125--27.63--49.83------
SIGA Technologies Inc172.96m83.97m601.64m45.007.253.597.123.481.161.162.412.351.020.586623.093,843,484.0049.5222.3456.2127.5682.0088.6548.5541.145.65--0.0029.5126.31-21.75100.76-30.57-26.67--
Revance Therapeutics Inc243.90m-283.87m605.29m597.00------2.48-3.17-3.212.64-1.240.44661.359.18408,542.70-51.97-55.55-61.40-63.2071.53---116.39-304.963.01-22.091.41--76.55128.849.10---0.3022--
Sinovac Biotech Ltd429.20m-130.73m639.90m3.04k------1.49-1.31-1.314.3186.810.03220.20191.08141,325.00-2.2336.14-3.3058.3792.0990.77-69.1965.8711.24--0.0262---69.9714.31-198.16--91.80--
Pacira Biosciences Inc690.31m63.59m670.22m711.0012.420.76214.860.97091.171.1712.3419.070.43291.836.77970,900.103.993.354.263.9874.0572.639.218.575.70--0.40130.001.2214.88163.72--0.8761--
Pliant Therapeutics Inc0.00-185.41m738.13m158.00--1.87-----3.09-3.090.006.500.00----0.00-35.03-33.24-37.15-35.39-------360.29----0.0711---83.69---30.83---16.89--
Avid Bioservices Inc142.36m-144.17m740.02m371.00--12.62--5.20-2.27-2.272.240.91920.36613.814.32383,714.30-37.08-0.826-57.59-1.206.2719.26-101.27-2.141.05-3.180.7343---6.2721.15-54,444.79--84.15--
Liquidia Corp14.84m-112.11m835.79m136.00--12.12--56.32-1.57-1.570.21020.82080.0993--4.04109,117.60-75.00-55.02-87.85-62.6969.5282.18-755.46-474.595.78-29.470.578--9.7545.23-91.40--66.93--
Phibro Animal Health Corp1.02bn2.42m902.42m1.94k374.203.5223.380.88670.05950.059525.116.341.042.596.11524,576.800.24733.930.30714.9030.8231.180.23743.771.641.760.655456.454.074.21-92.59-46.356.650.8548
PetIQ Inc1.13bn13.19m926.28m1.93k80.853.5616.440.81660.38020.380235.278.641.285.585.55586,823.101.54-4.321.96-5.2324.6320.051.21-3.661.682.090.63--19.5815.83104.42--4.96--
Evolus Inc237.26m-53.21m1.04bn304.00--54.03--4.40-0.9073-0.90734.020.30631.184.326.58869,084.30-26.42-40.92-34.63-59.7469.7265.43-22.43-80.462.67-2.000.8623--35.98--17.10--182.77--
Innoviva Inc330.50m145.42m1.21bn112.0011.711.826.543.661.651.654.1510.640.28211.023.782,950,857.0012.4126.2412.7828.5387.06--44.0076.8411.40--0.4019---6.303.53-15.99-14.57----
Data as of Sep 20 2024. Currency figures normalised to Liquidia Corp's reporting currency: US Dollar USD

Institutional shareholders

34.78%Per cent of shares held by top holders
HolderShares% Held
Caligan Partners LPas of 12 Sep 20248.14m10.60%
BlackRock Fund Advisorsas of 30 Jun 20243.80m4.95%
The Vanguard Group, Inc.as of 30 Jun 20243.25m4.23%
Findell Capital Management LLCas of 30 Jun 20242.40m3.13%
SSgA Funds Management, Inc.as of 30 Jun 20242.23m2.91%
Farallon Capital Management LLCas of 30 Jun 20242.06m2.68%
Vestal Point Capital LPas of 30 Jun 20241.83m2.38%
Geode Capital Management LLCas of 30 Jun 20241.31m1.71%
Kynam Capital Management LPas of 30 Jun 2024916.57k1.19%
Whitefort Capital Management, LPas of 30 Jun 2024774.48k1.01%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.